It’s a familiar story in the world of women’s health innovation: A startup launches with a sleek direct-to-consumer product, captures attention, builds a loyal user base - and then quietly pivots to enterprise.
In our sector where DTC models once dominated headlines and pitch decks, a shift is underway. More founders are stepping back from consumer-focused strategies in favor of B2B models and in pursuit of greater scale, more predictable revenue, and deeper integration into existing healthcare and benefits infrastructure.
Why Startups Start with B2C
Many women’s health companies begin as direct-to-consumer brands - and for good reason. The route to market is often faster, the barriers to entry lower and the opportunity to build trust directly with end-users is compelling. Community-building plays a central role in many of these brands' early traction, especially when addressing conditions and experiences that have long been underserved or misunderstood.
For founders passionate about advocacy and empowerment, the direct line to customers is not only strategic but often also deeply personal. It’s also a space where early feedback loops can shape product direction and validate demand. In the early stages, that kind of immediacy can be invaluable.
The DTC Reality Check
Despite the appeal, the path to building a sustainable DTC women’s health business is rarely straightforward. The cost of acquiring customers through digital channels has surged, especially on platforms like Meta and Google. Even with a differentiated product, competing for attention is expensive — and increasingly inefficient. Beyond that advertising restrictions continue to present challenges for entrepreneurs in our space.
Many products and services in women’s health are not covered by insurance or reimbursable, placing the financial burden squarely on consumers. This creates friction, particularly when building for underserved populations who may benefit most but have the least disposable income. Add to that the challenge of monetizing engagement-heavy offerings like education, coaching, or community platforms, and many startups eventually find themselves wrestling with the limits of their original go-to-market plans.
Why B2B Makes Sense
The shift to B2B isn't just about survival though - it's increasingly seen as a strategic evolution. By partnering with employers, health plans, or health systems, women’s health startups gain access to large, recurring revenue streams and a more scalable distribution model.
Employers, in particular, have emerged as key stakeholders. Rising interest in fertility, menopause, maternal mental health, and chronic condition management has put pressure on HR teams to expand benefits portfolios. In this context, women’s health companies (especially larger scale-ups) offer ready-made solutions with strong employee engagement potential and measurable outcomes.
Health systems and payers, while slower-moving, represent another pathway. For startups that can demonstrate clinical outcomes and cost savings, integration into care pathways and reimbursement models becomes a powerful, and sought-after long-term play.
From an investor standpoint, B2B also de-risks the business model. Enterprise contracts can offer more stability than consumer subscriptions, and the potential for multi-year agreements can significantly improve financial forecasts and fundraising narratives.
Case Studies: Startups That Shifted Gears
Calla Lily
Originally known for its consumer product tampliner, Calla Lily entered the menstrual care market with a hybrid tampon-liner innovation that made waves — even landing on TIME’s Best Inventions list. Today, the company is pivoting away from consumer products and into medical devices, having secured £1 million in NIHR funding for clinical trials of a progesterone delivery system designed to support women experiencing threatened miscarriage. The same technology has potential applications in IVF and hormone therapy — signaling a definitive move toward regulated, reimbursed clinical pathways.
Bloomlife
Bloomlife began as a consumer-focused pregnancy tracker. After running into the limits of DTC growth and facing regulatory challenges, the company shifted toward the clinical market. It now offers FDA-cleared remote monitoring devices and partners with insurers and health systems. With payers already reimbursing for its services and a growing portfolio that includes blood pressure and diabetes management tools, Bloomlife exemplifies how consumer insights can fuel a robust enterprise model in maternal care.
Wild.AI
Initially launched as an app for women tracking workouts around their cycles, Wild.AI was built to empower individual users with tailored insights. While the app remains consumer-facing, the company has since expanded into B2B via its Coach Dashboard and wearable integrations. A partnership with Zepp Health for example now embeds Wild.AI’s physiology-based training guidance directly into smartwatches - helping the company move from a standalone app to a platform embedded in third-party ecosystems.
Ema
Ema started as a maternal health chatbot for families and has since evolved into a flexible, white-label AI solution for businesses. Built on a clinically-vetted model trained on biopsychosocial inputs, Ema now powers partner platforms via API and integrations. Some of their partners include Willow, myUTI or PatientsLikeMe.
Valley Group
While not a pivot in the traditional sense, Valley - the company behind Lady-Comp, Daysy, and Teena - offers a compelling example of long-term strategy adjustment. Originally focused on selling proprietary fertility hardware directly to consumers, the company now licenses its core algorithm to partners. This licensing model creates a scalable, B2B revenue stream while allowing Valley to maintain its consumer product line - a hybrid strategy that leverages decades of data and scientific validation.
The Broader Implications
Overall I think that the shift from B2C to B2B isn’t just a tactical decision - it’s a reflection of a maturing women’s health innovation ecosystem. Founders are building not just with passion, but with discipline. They’re rethinking distribution, embedding into systems, and making hard calls about what it takes to scale impact.
And this is likely just the beginning.
As more startups grapple with the realities of going direct to consumer - and as interest from employers, payers, and health systems continues to grow - we’ll likely see even more companies take this path. For many, it won’t be a pivot of necessity, but a strategic move to build the kind of infrastructure women’s health has long been missing.
